Cargando…

Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses

BACKGROUND: Disulfidptosis is a novel type of programmed cell death. However, the value of disulfidptosis-related genes (DRGs) in the prediction of breast cancer prognosis is unclear. METHODS: RNA-seq data of 1231 patients, together with information on patient clinical characteristics and prognosis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shuyan, Zheng, Yiwen, Li, Shujin, Du, Yaoqiang, Liu, Xiaozhen, Tang, Hongchao, Meng, Xuli, Zheng, Qinghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645620/
https://www.ncbi.nlm.nih.gov/pubmed/37736788
http://dx.doi.org/10.1007/s00432-023-05372-z
_version_ 1785147391916113920
author Liu, Shuyan
Zheng, Yiwen
Li, Shujin
Du, Yaoqiang
Liu, Xiaozhen
Tang, Hongchao
Meng, Xuli
Zheng, Qinghui
author_facet Liu, Shuyan
Zheng, Yiwen
Li, Shujin
Du, Yaoqiang
Liu, Xiaozhen
Tang, Hongchao
Meng, Xuli
Zheng, Qinghui
author_sort Liu, Shuyan
collection PubMed
description BACKGROUND: Disulfidptosis is a novel type of programmed cell death. However, the value of disulfidptosis-related genes (DRGs) in the prediction of breast cancer prognosis is unclear. METHODS: RNA-seq data of 1231 patients, together with information on patient clinical characteristics and prognosis, were downloaded from TCGA. DRGs were identified between cancerous and non-cancerous tissues. The LASSO algorithm was used to assign half of the samples to the training set. Risk scores were used for construction of a prognostic model for risk stratification and prognosis prediction, and the clinical applicability was examined using a line diagram. The relationships between risk scores, immune cell infiltration, molecular subtypes, and responses to immunotherapy and chemotherapy were examined. RESULTS: We identified and obtained four DRG-related prognostic lncRNAs (AC009097.2, AC133552.5, YTHDF3-AS1, and AC084824.5), which were used for establishing the risk model. Longer survival was associated with low risk. The DRG-associated lncRNAs were found to independently predict patient prognosis. The AUCs under the ROCs for one-, three-, and 5-year survival in the training cohort were 0.720, 0.687, and 0.692, respectively. The model showed that the high-risk patients had reduced overall survival as well as high tumor mutation burdens. Furthermore, high-risk patients showed increased sensitivity to therapeutic drugs, including docetaxel, paclitaxel, and oxaliplatin. CONCLUSION: The risk score model was effective for predicting both prognosis and sensitivity to therapeutic drugs, suggesting its possible usefulness for the management of patients with breast cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-023-05372-z.
format Online
Article
Text
id pubmed-10645620
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-106456202023-11-14 Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses Liu, Shuyan Zheng, Yiwen Li, Shujin Du, Yaoqiang Liu, Xiaozhen Tang, Hongchao Meng, Xuli Zheng, Qinghui J Cancer Res Clin Oncol Research BACKGROUND: Disulfidptosis is a novel type of programmed cell death. However, the value of disulfidptosis-related genes (DRGs) in the prediction of breast cancer prognosis is unclear. METHODS: RNA-seq data of 1231 patients, together with information on patient clinical characteristics and prognosis, were downloaded from TCGA. DRGs were identified between cancerous and non-cancerous tissues. The LASSO algorithm was used to assign half of the samples to the training set. Risk scores were used for construction of a prognostic model for risk stratification and prognosis prediction, and the clinical applicability was examined using a line diagram. The relationships between risk scores, immune cell infiltration, molecular subtypes, and responses to immunotherapy and chemotherapy were examined. RESULTS: We identified and obtained four DRG-related prognostic lncRNAs (AC009097.2, AC133552.5, YTHDF3-AS1, and AC084824.5), which were used for establishing the risk model. Longer survival was associated with low risk. The DRG-associated lncRNAs were found to independently predict patient prognosis. The AUCs under the ROCs for one-, three-, and 5-year survival in the training cohort were 0.720, 0.687, and 0.692, respectively. The model showed that the high-risk patients had reduced overall survival as well as high tumor mutation burdens. Furthermore, high-risk patients showed increased sensitivity to therapeutic drugs, including docetaxel, paclitaxel, and oxaliplatin. CONCLUSION: The risk score model was effective for predicting both prognosis and sensitivity to therapeutic drugs, suggesting its possible usefulness for the management of patients with breast cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-023-05372-z. Springer Berlin Heidelberg 2023-09-22 2023 /pmc/articles/PMC10645620/ /pubmed/37736788 http://dx.doi.org/10.1007/s00432-023-05372-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Liu, Shuyan
Zheng, Yiwen
Li, Shujin
Du, Yaoqiang
Liu, Xiaozhen
Tang, Hongchao
Meng, Xuli
Zheng, Qinghui
Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
title Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
title_full Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
title_fullStr Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
title_full_unstemmed Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
title_short Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
title_sort integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on lasso and wgcna analyses
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645620/
https://www.ncbi.nlm.nih.gov/pubmed/37736788
http://dx.doi.org/10.1007/s00432-023-05372-z
work_keys_str_mv AT liushuyan integrativelandscapeanalysisofprognosticmodelbiomarkersandimmunogenomicsofdisulfidptosisrelatedgenesinbreastcancerbasedonlassoandwgcnaanalyses
AT zhengyiwen integrativelandscapeanalysisofprognosticmodelbiomarkersandimmunogenomicsofdisulfidptosisrelatedgenesinbreastcancerbasedonlassoandwgcnaanalyses
AT lishujin integrativelandscapeanalysisofprognosticmodelbiomarkersandimmunogenomicsofdisulfidptosisrelatedgenesinbreastcancerbasedonlassoandwgcnaanalyses
AT duyaoqiang integrativelandscapeanalysisofprognosticmodelbiomarkersandimmunogenomicsofdisulfidptosisrelatedgenesinbreastcancerbasedonlassoandwgcnaanalyses
AT liuxiaozhen integrativelandscapeanalysisofprognosticmodelbiomarkersandimmunogenomicsofdisulfidptosisrelatedgenesinbreastcancerbasedonlassoandwgcnaanalyses
AT tanghongchao integrativelandscapeanalysisofprognosticmodelbiomarkersandimmunogenomicsofdisulfidptosisrelatedgenesinbreastcancerbasedonlassoandwgcnaanalyses
AT mengxuli integrativelandscapeanalysisofprognosticmodelbiomarkersandimmunogenomicsofdisulfidptosisrelatedgenesinbreastcancerbasedonlassoandwgcnaanalyses
AT zhengqinghui integrativelandscapeanalysisofprognosticmodelbiomarkersandimmunogenomicsofdisulfidptosisrelatedgenesinbreastcancerbasedonlassoandwgcnaanalyses